Background: Clinical data suggested that pentraxin-3 is a biomarker for atherosclerosis due to its role in inflammatory processes since it exerts unfavorable effects on the course of atherosclerosis, stimulates plaque formation, and augments vascular inflammation. Objective: The aims of this study were to measure the level of serum pentraxin-3 in patients with suspected coronary artery disease (CAD) and to determine whether it was associated with the severity of CAD. Material and Methods: The serum pentraxin-3 level was measured by enzyme-linked immunosorbent assay in 80 patients who were referred for elective coronary angiography due to positive stress test results. SYNTAX score was used to determine the severity of CAD. Results: The study cohort consisted of 45 (56.25%) males and 35 (43.75%) females with a mean age of 55 ± 9.8 years. The mean serum pentraxin-3 level was 3.79 ± 1.38 ng/ml, and the mean SYNTAX score was 15.8 ± 11.3. A significant correlation was observed between pentraxin-3 level and SYNTAX score (r = 0.459, p < 0.001). The level of pentraxin-3 was significantly higher in patients with SYNTAX scores of ≥33 compared with patients who scored 23 -32 or ≤22 (p = 0.002). Conclusion: The serum level of inflammatory marker pentraxin-3 is increased in patients with CAD and is correlated with the severity of CAD.
kines in endothelium, macrophages, smooth muscle cells, and dendritic cells [2] .
Clinical data suggested that pentraxin-3 is a biomarker for atherosclerosis due to its role in inflammatory processes since it produces unfavorable effects on the course of atherosclerosis, stimulates plaque formation, and augments vascular inflammation [3] . Patients with vulnerable coronary plaque showed higher pentraxin-3 levels than those with stable plaque [4] .
Patients with endothelial dysfunction exhibited elevated pentraxin-3, and the serum level of pentraxin-3 was associated with the degree of the endothelial dysfunction [5] . In addition, elevated pentraxin-3 was reported in patients with systemic hypertension [6] . Furthermore, pentraxin-3 was stated to be a biomarker of acute myocardial injury [7] .
Clinicians use SYNTAX score to identify the severity of CAD. It yields predictive data about the outcomes of patients with CAD, and indicates the type of coronary revascularization (i.e., percutaneous or surgical) [8] [9] .
A few studies have explored the association between pentraxin-3 and the degree of coronary atherosclerosis. One study reported a significant correlation between serum levels of pentraxin-3 and the number of diseased coronary arteries. Another one reported an association between pentraxin-3 levels and Gensini score [10] [11] . The aims of this study were to measure the level of serum pentraxin-3 in patients with suspected CAD and to determine whether it was associated with the severity of CAD.
Methods

Study Population
A total of 80 patients (mean age: 55 ± 9.8 years) were recruited in this study. The inclusion criteria were patients with suspected CAD who were referred for elective coronary angiography due to positive results of a stress test between May 2017 and March 2018. The exclusion criteria were defined as acute coronary syndrome, previous coronary revascularization, significant valvular heart disease, preexisting cardiomyopathies, chronic kidney disease, liver cirrhosis, and patients with CAD and a SYNTAX score of 0 (i.e., stenosis of less than 50%).
The study was approved by the local ethics committee. Informed consent was obtained from the patients before they became involved in the study.
As part of the study, risk factors of CAD (diabetes mellitus, hypertension, dyslipidemia, family history, and smoking) were reported, and body mass index was calculated. In addition, the echocardiographic data, including the left ventricular ejection fraction, was reviewed and reported. Further, the serum levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, serum creatinine, and fasting glucose were analyzed.
Measurement of Serum Pentraxin-3
The protein concentration in serum samples collected after 12 h of fasting was World Journal of Cardiovascular Diseases estimated using the BCA protein estimation kit (ThermoFisher Scientific, USA).
Appropriate sample dilution was performed prior to enzyme-linked immunosorbent assay (ELISA) of pentraxin-3. Standard stock was serially diluted, and all samples were loaded onto a pre-coated ELISA plate. The procedure was performed according to the instructions on the datasheet of the human pentraxin-3 ELISA kit (#SEK411Hu, Cloud-Clone Corp., Katy, TX, USA). The concentration of pentraxin-3 in control and patient samples was determined using the standard curve equation.
Cardiac Catheterization
Cardiac catheterization was performed using a radial approach in 72 patients and a femoral approach in 8 patients. Usual views of coronary angiography were taken. The assessment of coronary artery stenosis was done according to the recommendations of American Heart Association. The extent of disease is defined as left main disease, one-vessel, two-vessel, or three-vessel disease. Significant coronary lesion was defined by the presence of a stenosis of ≥50% diameter reduction [12] . Coronary angiograms were stored on compact discs in DICOM format. SYNTAX score was used to determine the severity of CAD. An online computer program (http://www.syntaxscore.com/calculator/start.htm) consisting of 12 sequential questions was used to calculate the score. Any lesion causing ≥50% stenosis in a vessel ≥ 1.5 mm in diameter was included [13] . The main factors used to calculate the score of each lesion are as follows: dominant coronary artery, diseased segments, total occlusion, trifurcation or bifurcation, lesions leading to severe tortuosity, lesion with aorto-ostial site, lesion more than 20 mm in length, severe calcification of the lesion, presence of thrombus, and diffusely diseased and narrowed segment. Patients who had a normal coronary angiogram were included in the control group. Patients with CAD were subdivided into three groups according to their SYNTAX scores. The first group included patients with mild CAD (SYNTAX score: ≤22), the second group included those with moderate CAD (SYNTAX score: 23 -32) , and the third group included those with severe CAD (SYNTAX score: ≥33). Patients with a score of 0 were excluded.
Statistical Analysis
The data were analyzed using the IBM SPSS software package, version 20.0 (IBM Corp, Armonk, NY, USA). The Kolmogorov-Smirnov, Shapiro-Wilk, and D'Agostino tests were used to verify the normality of the distribution of the variables, and comparisons between groups were assessed using a chi-squared test (Fisher or Monte Carlo) for the categorical variables. A Student's t-test was used to compare the groups in terms of normally distributed quantitative variables, and the Mann-Whitney U test was used to compare the groups in terms of abnormally distributed quantitative variables. Spearman's and Pearson's coefficient tests were used to determine the correlations between the variables. Results below 0.5 were considered to be significant.
Results
Patient's Characteristics
The study cohort consisted of 45 (56.25%) males and 35 (43.75%) females with a mean age of 55 ± 9.8 years. Of the cohort, 31 (38.75%) patients were smokers, 17 (21.25%) patients had a family history of CAD, 34 (42.5%) patients were hypertensive, and 33 (41.25%) patients were diabetic. The mean SYNTAX score was 15.8 ± 11.3, and the mean serum pentraxin-3 level was 3.79 ± 1.38 ng/ml.
Based on the results of coronary angiography, 12 (15%) patients with normal coronary angiography-5 males and 7 females with a mean age of 53.5 ± 9.5 years-and served as a control group. 68 (75%) patients-40 males and 28 females with a mean age of 55.3 ± 10 years-had CAD. No significant difference was found between the two groups regarding age, gender, prevalence of CAD risk factors, lipid profile, or serum creatinine (p > 0.05). The mean pentraxin-3 level was 3.1 ± 0.9 ng/ml in control group and 3.9 ± 1.4 ng/ml in CAD group (p = 0.038) ( Table 1 and Table 2 , Figure 1 ). 
Serum Pentraxin-3 Levels in the Studied Groups and Association with SYNTAX Score
The mean serum pentraxin-3 levels in Groups I, II, and III were 3.5 ± 1.1, 4.3 ± 1.3, and 5.4 ± 2 ng/ml, respectively (p = 0.002) ( Table 3 and Figure 2 ). Pentraxin-3 level was associated with SYNTAX score (r = 0.459, p < 0.001). There was also a significant association between serum pentraxin-3 and LDL cholesterol (r = 0.285, p = 0.018) ( Table 4 and Figure 3 ). Table 4 . Correlation between pentraxin-3 and studied parameters in CAD patients (n = 68).
Pentraxin-3 
Discussion
Considered an acute-phase immunity protein due to its role in innate immunity, The results of this study agree with other researches. For instance, Nerkiz et al.
reported higher levels of pentraxin-3 in patients with CAD than in those without. In their study, they did not use SYNTAX score to assess the severity of CAD, but the number of affected vessels (≤50% stenosis; disease in one, two, three, or four vessels). They concluded that pentraxin-3 level was significantly increased proportionate to the number of affected coronary arteries [10] . In ad- as assessed by optical coherence tomography, concluding that serum pentraxin-3 level could be used to determine plaque vulnerability [27] .
The prognostic role of pentaraxin-3 was investigated by Jenny et al., who studied the link between pentraxin-3 and asymptomatic cardiovascular disease and reported higher pentraxin-3 levels in patients with asymptomatic cardiovascular disease compared to healthy subjects. Furthermore, they found a positive correlation between pentraxin-3 and both cardiovascular disease and cardiovascular mortality [28] . 
Limitations of the Study
SYNTAX score depends on visual assessment of coronary lesions. Therefore, it is World Journal of Cardiovascular Diseases better to use intravascular coronary ultrasonography to evaluate coronary plaque. The small number of patients is another limitation. Further, the present study had no prognostic value. Finally, it would have been better to estimate other documented inflammatory markers, such as C-reactive protein.
Conclusion
The serum level of inflammatory marker pentraxin-3 is increased in patients with CAD and is correlated with the severity of CAD.
